Quick Answer
Sagimet Biosciences Inc. reported Cash and Equivalents of $35.02 million for fiscal year 2025.
Sagimet Biosciences Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $35.02M | -53.8% |
| 2024 | $75.84M | +0.9% |
| 2023 | $75.14M | +47456.3% |
| 2022 | $158.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.50M | -57.8% | -23.2% |
| June 30, 2025 | $42.33M | -55.9% | -34.6% |
| March 31, 2025 | $64.72M | -63.4% | -14.7% |
| December 31, 2024 | $75.84M | +0.9% | -1.5% |
| September 30, 2024 | $77.01M | -24.4% | -19.7% |
| June 30, 2024 | $95.96M | +418.5% | -45.7% |
| March 31, 2024 | $176.78M | — | +135.3% |
| December 31, 2023 | $75.14M | +47456.3% | -26.2% |
- Sagimet Biosciences Inc. showed a decrease of -53.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Sagimet Biosciences Inc.’s cash and equivalents has grown by 22065.2% (from $158.0 thousand to $35.02 million).
- The most recent figure is from Sagimet Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: